BAY 3713372 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment, BAY 3713372, for individuals with specific types of solid tumors known as MTAP-deleted cancers. The aim is to determine if this treatment can target and kill cancer cells while sparing healthy cells. Researchers seek to identify the safest and most effective dose and assess the treatment's efficacy over time. This trial may suit individuals with MTAP-deleted tumors who have at least one measurable lesion for tracking improvement. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in humans.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss your current medications with the study team to get specific guidance.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that BAY 3713372 remains in the early stages of human testing. As this is the first study of the treatment in humans, solid information on its safety is limited.
The main goal of current studies is to determine the safety of BAY 3713372 and how the body processes it. Researchers examine the frequency and severity of side effects and assess whether any side effects are serious enough to warrant stopping the treatment.
In this early-stage trial, the treatment undergoes testing to establish a safe dose. Consequently, there may be limited information on how well participants tolerate the treatment. However, careful monitoring of side effects and dose adjustments aim to ensure participant safety.12345Why are researchers excited about this study treatment for cancer?
Most treatments for cancers with MTAP deletions, like certain types of lung and pancreatic cancers, typically focus on chemotherapy or targeted therapies that attack specific cancer growth pathways. But BAY 3713372 is different because it targets the vulnerabilities created by the absence of MTAP, potentially providing a more precise attack on cancer cells. Researchers are excited because BAY 3713372 can be used as a monotherapy or in combination with other treatments, which might enhance its effectiveness and broaden its applicability. Additionally, its unique mechanism of action could lead to improved outcomes for patients with these challenging cancer types.
What evidence suggests that this trial's treatment, BAY 3713372, could be effective for MTAP-deleted solid tumors?
Research has shown that BAY 3713372 targets cancers with MTAP deletions by blocking a protein called PRMT5, which plays a role in many cancers, such as lung and breast cancer. Blocking PRMT5 might help stop cancer cells from growing. Early results suggest that this treatment could target cancer cells while sparing healthy ones. Although more information is needed, this approach appears promising for treating hard-to-treat tumors. Participants in this trial will join various treatment arms, including dose escalation and dose expansion cohorts, to evaluate the safety and efficacy of BAY 3713372 in different cancer types.12367
Are You a Good Fit for This Trial?
This trial is for individuals with MTAP-deleted solid tumors, such as uterine cancer. Participants will be closely monitored and must visit the study site multiple times. They should not have medical conditions that exclude them from safely receiving BAY 3713372, but specific exclusion criteria are not listed here.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BAY 3713372 starting from low to high doses to find the highest safe dose
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Follow-up
Study doctors contact participants every 3 months to learn about their health
What Are the Treatments Tested in This Trial?
Interventions
- BAY 3713372
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bayer
Lead Sponsor
Bill Anderson
Bayer
Chief Executive Officer since 2023
BSc in Chemical Engineering from the University of Texas, MSc in Chemical Engineering and Management from MIT
Michael Devoy
Bayer
Chief Medical Officer since 2014
MD, PhD